title: Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy?
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, NY jhaverik@mskcc.org.
authors.forename: Komal
authors.initials: K
authors.lastname: Jhaveri
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Gary A
authors.initials: GA
authors.lastname: Ulaner
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Maura N
authors.initials: MN
authors.lastname: Dickler
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D011877:Radionuclide Imaging
chemical_list: D019788:Fluorodeoxyglucose F18